Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

Rhea-AI Summary

Eledon Pharmaceuticals (Nasdaq: ELDN) will be participating in the Leerink Partners Therapeutics Forum focused on Inflammation & Immunology (I&I) and Metabolism. The event is scheduled for July 9, 2024, in Boston, MA. During the forum, Eledon's management team will engage in one-on-one meetings with investors and industry professionals. This participation highlights Eledon's active role in the field of therapeutics and its ongoing efforts to engage with key stakeholders.

IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, 2024, in Boston, MA.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

FAQ

When will Eledon participate in the Leerink Partners Therapeutics Forum?

Eledon will participate in the Leerink Partners Therapeutics Forum on July 9, 2024.

What is the focus of the Leerink Partners Therapeutics Forum?

The focus of the Leerink Partners Therapeutics Forum is on Inflammation & Immunology (I&I) and Metabolism.

Where is the Leerink Partners Therapeutics Forum taking place?

The Leerink Partners Therapeutics Forum will take place in Boston, MA.

What will Eledon Pharmaceuticals' management team do at the Leerink Partners Therapeutics Forum?

Eledon's management team will host one-on-one meetings with investors and industry professionals.

What is the significance of Eledon's participation in the Leerink Partners Therapeutics Forum for ELDN stock?

Eledon's participation in the forum demonstrates the company's proactive engagement with key stakeholders, which can positively impact investor confidence and ELDN stock performance.